J Rhinol.  2005 May;12(1):32-38.

The Inhibitory Effect of Anti-P-Selectin, Anti-PSGL-1 and Anti-CD49d Antibodies on Experimental Allergic Airway Inflammation in Mice

  • 1Department of Otolaryngology, College of Medicine, Chungnam National University, Daejeon, Korea. ksrha@cnu.ac.kr
  • 2Department of Otolaryngology, College of Medicine, Yanbian University, Yanji, China.


BACKGROUND AND OBJECTIVES: Eosinophil recruitment in allergic inflammation is dependent on the interactions between adhesion molecules. The objective of this study was to determine whether blocking of P-selectin glycoprotein ligand-1 (PSGL-1), P-selectin or CD49d adhesion molecules using monoclonal antibodies can reduce eosinophil recruitment in mice with the airway allergy.
Seven different groups of mice were used. One experimental group of mice (group A) served as naive control and sensitized with phosphate-buffered saline (PBS). Six experimental groups of mice (groups B to G) were sensitized to ovalbumin (OVA). The mice in group B were treated with PBS before OVA aerosol challenge and served as positive controls. The mice in other remaining groups were treated with monoclonal antibodies (mAb) against specific adhesion molecules before OVA challenge; anti-P-selectin mAb (group C), anti-PSGL-1 mAb (group D), anti-CD49d mAb (group E), anti-P-selectin mAb & anti-CD49d mAb (group F), anti PSGL-1 mAb & anti-CD49d mAb (group G). Eosinophils in the nasal mucosa and bronchoalveolar lavage (BAL) fluid in each animal group were measured.
Mucosal eosinophilic infiltrations were significantly reduced at the mice in the group C, F or G compared with group B. Eosinophils in BAL fluid were significantly reduced only at the group C mice.
These results suggest that blockade of P-selectin is superior to blockade of PSGL-1 or CD49d in the inhibitory effect against eosinophil recruitment.


Allergy; Animal experimentation; Cell adhesion molecules; P-selectin; Eosinophils
Full Text Links
  • JR
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr